Gene · 10481
Papers1,917
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,917
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer. | Heliyon | 2024 | 38298632 | PubTator, text mining | PubMed |
| ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling. | Cancers (Basel) | 2024 | 38254880 | PubTator, text mining | PubMed |
| How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update. | Cancers (Basel) | 2024 | 38254807 | PubTator, text mining | PubMed |
| It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective. | Cancers (Basel) | 2024 | 38254784 | PubTator, text mining | PubMed |
| Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics Approach. | Biomolecules | 2024 | 38254687 | PubTator, text mining | PubMed |
| Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. | NPJ Genom Med | 2024 | 38253539 | PubTator, text mining | PubMed |
| The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. | Clin Cancer Res | 2024 | 38236581 | PubTator, text mining | PubMed |
| MALAT1 promotes FOXA1 degradation by competitively binding to miR-216a-5p and enhancing neuroendocrine differentiation in prostate cancer. | Transl Oncol | 2024 | 38235618 | PubTator, text mining | PubMed |
| Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development. | Cancers (Basel) | 2024 | 38201640 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant phenotype of gastric cancer. | BMC Gastroenterol | 2024 | 38200441 | PubTator, text mining | PubMed |
| HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation. | Heliyon | 2024 | 38192826 | PubTator, text mining | PubMed |
| Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. | Cell Death Dis | 2024 | 38177102 | PubTator, text mining | PubMed |
| Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. | Signal Transduct Target Ther | 2024 | 38169461 | PubTator, text mining | PubMed |
| BAF45D-binding to HOX genes was differentially targeted in H9-derived spinal cord neural stem cells. | Sci Rep | 2024 | 38168763 | PubTator, text mining | PubMed |
| Deciphering the emerging landscape of HOX genes in cardiovascular biology, atherosclerosis and beyond (Review). | Int J Mol Med | 2024 | 38131178 | PubTator, text mining | PubMed |
| FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate Cancer. | Cancer Res Commun | 2024 | 38112617 | PubTator, text mining | PubMed |
| Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. | Eur Urol | 2024 | 38104015 | PubTator, text mining | PubMed |
| Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. | Nucleic Acids Res | 2024 | 38015476 | PubTator, text mining | PubMed |
| Dynamic chromatin accessibility landscapes of osteoblast differentiation and mineralization. | Biochim Biophys Acta Mol Basis Dis | 2024 | 37931716 | PubTator, text mining | PubMed |
| Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis. | Breast Cancer Res Treat | 2024 | 37878151 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10481/papers?page=7